Zacks Investment Research Lowers Swedish Orphan Biovitrum (SWTUY) to Hold

Swedish Orphan Biovitrum (OTCMKTS:SWTUY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.

According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “

How to Become a New Pot Stock Millionaire

Shares of SWTUY stock opened at $17.41 on Thursday. Swedish Orphan Biovitrum has a 1 year low of $12.55 and a 1 year high of $17.70. The firm has a market cap of $4,744.36, a PE ratio of 49.74, a PEG ratio of 0.77 and a beta of 1.52.

TRADEMARK VIOLATION WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3336891/zacks-investment-research-lowers-swedish-orphan-biovitrum-swtuy-to-hold.html.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.

Get a free copy of the Zacks research report on Swedish Orphan Biovitrum (SWTUY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Sojourn Reaches Market Capitalization of $44,783.00
Sojourn Reaches Market Capitalization of $44,783.00
Nework Hits 24-Hour Volume of $3.99 Million
Nework Hits 24-Hour Volume of $3.99 Million
Brokerages Anticipate FLIR Systems  to Post $0.43 EPS
Brokerages Anticipate FLIR Systems to Post $0.43 EPS
Strayer Education  Given Consensus Rating of “Buy” by Brokerages
Strayer Education Given Consensus Rating of “Buy” by Brokerages
Lionsgate  Given Average Rating of “Buy” by Analysts
Lionsgate Given Average Rating of “Buy” by Analysts
 Reaches Market Cap of $0.00
Reaches Market Cap of $0.00


© 2006-2018 Ticker Report. Google+.